Manuel Paez-Escamilla
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Manuel Paez-Escamilla has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- J. William Harbour
Department of Ophthalmology and Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX
9 shared publications Scott D. Walter
Bascom Palmer Eye Institute, Miller School of Medicine, University of Miami, Miami, Florida
6 shared publicationsChristina L. Decatur
Bascom Palmer Eye Institute, Miller School of Medicine, University of Miami, Miami, Florida
3 shared publicationsJ. William Harbour
Department of Ophthalmology, University of Miami Bascom Palmer Eye Institute, Miami, FL
3 shared publicationsArnold M. Markoe
Department of Radiation Oncology, University of Miami/Jackson Memorial Hospital, Miami, FL
2 shared publications- Jay Chhablani
UPMC Eye Center, University of Pittsburgh, Pittsburgh, Pennsylvania
2 shared publications
Latest Publications
- 4 November 2022
- Published by Taylor & Francis in Ophthalmic Genetics
- Vol. 44 (4) , 385-388
Melphalan toxicity following treatment of retinoblastoma identified by pattern electroretinogram
To describe a patient with retinoblastoma and subsequent maculopathy unrelated to the tumor but related to intra-arterial melphalan documented by pattern electroretinography.Comprehensive ophthalmi...
- 4 November 2022
- Published by Taylor & Francis in Ophthalmic Genetics
- Vol. 44 (4) , 385-388
Melphalan toxicity following treatment of retinoblastoma identified by pattern electroretinogram
To describe a patient with retinoblastoma and subsequent maculopathy unrelated to the tumor but related to intra-arterial melphalan documented by pattern electroretinography.Comprehensive ophthalmi...
- 25 July 2022
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- Vol. 31 (7) , 1533-1536
Bleb Associated Xen Gel Stent Endophthalmitis: A Case Report and Review of Literature
To report a case of a unique late complication of the Xen gel stent, stent-related endophthalmitis was preceded by flattening of the bleb. A 63-year-old female was presented with late-onset endophthalmitis preceded by flattening of the bleb two years post-insertion of Xen gel stent. B-scan of the posterior chamber revealed vitritis and hyaloid condensation, with no viral, fungal, or bacterial pathologies identified on anterior chamber tap. The patient’s eye responded to injections of intravitreal antibiotics. Endophthalmitis can occur as late as 2 years after implantation of glaucoma drainage device implants (GDIs) like the Xen gel stent if bleb flattening or leaking leads to contact of the stent with the conjunctiva. Therefore, in case of blebs getting flat, ophthalmologists should watch them more often. Intravitreal antibiotics may also be effective rather than surgical removal in the case of a non-eroded stent complicated by endophthalmitis.
- 25 July 2022
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- Vol. 31 (7) , 1533-1536
Bleb Associated Xen Gel Stent Endophthalmitis: A Case Report and Review of Literature
To report a case of a unique late complication of the Xen gel stent, stent-related endophthalmitis was preceded by flattening of the bleb. A 63-year-old female was presented with late-onset endophthalmitis preceded by flattening of the bleb two years post-insertion of Xen gel stent. B-scan of the posterior chamber revealed vitritis and hyaloid condensation, with no viral, fungal, or bacterial pathologies identified on anterior chamber tap. The patient’s eye responded to injections of intravitreal antibiotics. Endophthalmitis can occur as late as 2 years after implantation of glaucoma drainage device implants (GDIs) like the Xen gel stent if bleb flattening or leaking leads to contact of the stent with the conjunctiva. Therefore, in case of blebs getting flat, ophthalmologists should watch them more often. Intravitreal antibiotics may also be effective rather than surgical removal in the case of a non-eroded stent complicated by endophthalmitis.
- Open Access
- 29 January 2022
- Published by Elsevier in American Journal of Ophthalmology Case Reports
- Vol. 25, 101373
Recovery of vision after treatment of hemodialysis related bilateral optic nerve ischemia
- 29 January 2022
- Published by Elsevier in American Journal of Ophthalmology Case Reports
- Vol. 25, 101373
Open AccessRecovery of vision after treatment of hemodialysis related bilateral optic nerve ischemia
- 1 March 2021
- Published by Elsevier in Survey of Ophthalmology
- Vol. 66 (2) , 153-182
Age-related macular degeneration masqueraders: From the obvious to the obscure
- 1 March 2021
- Published by Elsevier in Survey of Ophthalmology
- Vol. 66 (2) , 153-182
Age-related macular degeneration masqueraders: From the obvious to the obscure
- 1 July 2020
- Published by Elsevier in Survey of Ophthalmology
- Vol. 65 (4) , 451-457
Unique optical coherence tomographic features in age-related macular degeneration
- 1 July 2020
- Published by Elsevier in Survey of Ophthalmology
- Vol. 65 (4) , 451-457
Unique optical coherence tomographic features in age-related macular degeneration
- 1 December 2019
- Published by American Medical Association (AMA) in JAMA Ophthalmology
- Vol. 137 (12) , 1434-1439
Intraocular Metastasis in Unilateral Multifocal Uveal Melanoma Without Melanocytosis or Germline BAP1 Mutations
Importance There has been speculation on the pathogenesis of unilateral multifocal uveal melanoma, but there remains no convincing explanation. Genetic analysis suggests that unilateral multifocal uveal melanoma may represent intraocular metastasis with increased risk of systemic metastasis. Objective To evaluate the pathogenesis of unilateral multifocal uveal melanoma. Design, Setting, and Participants This clinical case series was conducted in tertiary academic ocular oncology referral centers and included patients with unilateral multifocal uveal melanoma. Main Outcomes and Measures Gene expression and mutation profiling of tumor samples. Results Four patients (all male; age range, 54-77 years) who were diagnosed with uveal melanoma were treated with plaque brachytherapy, and subsequently developed a second discrete uveal melanoma in the same eye were included. None demonstrated ocular or oculodermal melanocytosis. All 8 tumors available for analysis exhibited class 2 gene expression profiles. In all 4 cases, the initial and subsequent tumors were available for targeted DNA sequencing and identical driver mutations were present in both tumors. Data were collected from September 2015 to August 2018. Conclusions and Relevance Unilateral multifocal uveal melanoma in the absence of ocular melanocytosis appears to occur preferentially in tumors with the class 2 gene expression profile and aBRCA1-associated protein 1 gene (BAP1) mutation. The presence of identicalBAP1mutations in multiple tumors in the same eye in the absence of a germlineBAP1mutation suggests intraocular metastasis rather than independent primary tumors. These findings indicate that the first site of metastasis can be within the eye itself and suggest that patients with unilateral multifocal uveal melanoma may be at increased risk of systemic metastasis.
- 1 December 2019
- Published by American Medical Association (AMA) in JAMA Ophthalmology
- Vol. 137 (12) , 1434-1439
Intraocular Metastasis in Unilateral Multifocal Uveal Melanoma Without Melanocytosis or Germline BAP1 Mutations
Importance There has been speculation on the pathogenesis of unilateral multifocal uveal melanoma, but there remains no convincing explanation. Genetic analysis suggests that unilateral multifocal uveal melanoma may represent intraocular metastasis with increased risk of systemic metastasis. Objective To evaluate the pathogenesis of unilateral multifocal uveal melanoma. Design, Setting, and Participants This clinical case series was conducted in tertiary academic ocular oncology referral centers and included patients with unilateral multifocal uveal melanoma. Main Outcomes and Measures Gene expression and mutation profiling of tumor samples. Results Four patients (all male; age range, 54-77 years) who were diagnosed with uveal melanoma were treated with plaque brachytherapy, and subsequently developed a second discrete uveal melanoma in the same eye were included. None demonstrated ocular or oculodermal melanocytosis. All 8 tumors available for analysis exhibited class 2 gene expression profiles. In all 4 cases, the initial and subsequent tumors were available for targeted DNA sequencing and identical driver mutations were present in both tumors. Data were collected from September 2015 to August 2018. Conclusions and Relevance Unilateral multifocal uveal melanoma in the absence of ocular melanocytosis appears to occur preferentially in tumors with the class 2 gene expression profile and aBRCA1-associated protein 1 gene (BAP1) mutation. The presence of identicalBAP1mutations in multiple tumors in the same eye in the absence of a germlineBAP1mutation suggests intraocular metastasis rather than independent primary tumors. These findings indicate that the first site of metastasis can be within the eye itself and suggest that patients with unilateral multifocal uveal melanoma may be at increased risk of systemic metastasis.
- 1 September 2019
- Published by SLACK, Inc. in Ophthalmic Surgery, Lasers and Imaging Retina
- Vol. 50 (9) , 573-579
Intraocular Dissemination of Uveal Melanoma Cells Following Radiotherapy: Evolving Management Over the Past Decade
BACKGROUND AND OBJECTIVE: To describe the presentation and the authors' evolving management strategy for intraocular dissemination of uveal melanoma cells following radiotherapy during the past decade. PATIENTS AND METHODS: Patients with uveal melanoma who developed intraocular dissemination of pigmented cells following radiotherapy. Histopathology was available in two cases. RESULTS: Four patients underwent treatment for progressive intraocular dissemination of uveal melanoma cells at 9 to 41 months following I-125 plaque radiotherapy (three patients) or proton beam radiotherapy (one patient). Treatments included primary enucleation (one patient), vitrectomy followed later by enucleation (one patient), and vitrectomy followed by intravitreal chemotherapy (two patients). Enucleated eyes demonstrated diffuse invasion of intraocular tissues by viable melanoma cells. No patient has developed systemic metastasis to date. CONCLUSIONS: Intraocular dissemination of pigmented cells following radiotherapy for uveal melanoma should raise suspicion for viable invasive melanoma cells. Prompt vitrectomy with intravitreal chemotherapy can be effective in avoiding enucleation in selected cases. [ Ophthalmic Surg Lasers Imaging Retina . 2019;50:573–579.]
- 1 September 2019
- Published by SLACK, Inc. in Ophthalmic Surgery, Lasers and Imaging Retina
- Vol. 50 (9) , 573-579
Intraocular Dissemination of Uveal Melanoma Cells Following Radiotherapy: Evolving Management Over the Past Decade
BACKGROUND AND OBJECTIVE: To describe the presentation and the authors' evolving management strategy for intraocular dissemination of uveal melanoma cells following radiotherapy during the past decade. PATIENTS AND METHODS: Patients with uveal melanoma who developed intraocular dissemination of pigmented cells following radiotherapy. Histopathology was available in two cases. RESULTS: Four patients underwent treatment for progressive intraocular dissemination of uveal melanoma cells at 9 to 41 months following I-125 plaque radiotherapy (three patients) or proton beam radiotherapy (one patient). Treatments included primary enucleation (one patient), vitrectomy followed later by enucleation (one patient), and vitrectomy followed by intravitreal chemotherapy (two patients). Enucleated eyes demonstrated diffuse invasion of intraocular tissues by viable melanoma cells. No patient has developed systemic metastasis to date. CONCLUSIONS: Intraocular dissemination of pigmented cells following radiotherapy for uveal melanoma should raise suspicion for viable invasive melanoma cells. Prompt vitrectomy with intravitreal chemotherapy can be effective in avoiding enucleation in selected cases. [ Ophthalmic Surg Lasers Imaging Retina . 2019;50:573–579.]
- 1 May 2019
- Published by Elsevier in Brachytherapy
- Vol. 18 (3) , 404-410
Dosimetric comparison of circular Eye Physics and Collaborative Ocular Melanoma Study plaques to treat uveal melanoma
- 1 May 2019
- Published by Elsevier in Brachytherapy
- Vol. 18 (3) , 404-410
Dosimetric comparison of circular Eye Physics and Collaborative Ocular Melanoma Study plaques to treat uveal melanoma
- 1 February 2019
- Published by Elsevier in Journal of American Association for Pediatric Ophthalmology and Strabismus
- Vol. 23 (1) , 51-53
Persistent fetal vasculature presenting with axial elongation and platyphakia
- 1 February 2019
- Published by Elsevier in Journal of American Association for Pediatric Ophthalmology and Strabismus
- Vol. 23 (1) , 51-53
Persistent fetal vasculature presenting with axial elongation and platyphakia
- 1 January 2019
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 197, 168-179
Are Risk Factors for Growth of Choroidal Nevi Associated With Malignant Transformation? Assessment With a Validated Genomic Biomarker
- 1 January 2019
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 197, 168-179
Are Risk Factors for Growth of Choroidal Nevi Associated With Malignant Transformation? Assessment With a Validated Genomic Biomarker